John Gribben is Hamilton Fairley Professor of Medical Oncology at Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary University of London, UK. After doctoral studies at University College London, where he was the recipient of a Wellcome Trust Fellowship Award, he received a Fogarty International Fellowship to continue postdoctoral training at the Dana- Farber Cancer Institute, Harvard Medical School, in Boston, USA. In 1991, he was appointed to the faculty at Harvard Medical School, where he remained as Associate Professor of Medicine and an attending physician until returning to London in 2005. He is an internationally recognized translational cancer researcher, and the author of more than 490 manuscripts and 60 book chapters. He is a Fellow of the Royal College of Physicians and of the Royal College of Pathologists. He was elected as a member of the American Society for Clinical Investigation and elected as a Fellow of the Academy of Medical Science.
Professor Gribben’s primary research interests include advances in the management of lymphoma and CLL, immunotherapy of cancer (including stem-cell transplantation), the identification of tumor antigens, and eradication of minimal residual disease. He was awarded the prestigious Binet-Rai Medal in 2017 for his outstanding contribution to research into CLL. His research work focuses on the impact of B cell malignancies on the host immune system, and delineating the molecular mechanisms for this. He is Board member of the international workshop for CLL. He is the Chair of the international workshop for NHL and co-Chair of the international workshop for CART. He serves on the Executive Board of the European Hematology Association (EHA) and as President of EHA from 2019-2021.
Updated: September 2021